Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta

Joel R. Chamberlain, David R. Deyle, Ulrike Schwarze, Peirong Wang, Roli K. Hirata, Yi Li, Peter H. Byers, David W. Russell

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) are adult cells with the capacity to differentiate into multiple cell types, including bone, fat, cartilage, and muscle cells. In order to effectively utilize autologous MSCs in cell-based therapies, precise genetic manipulations are required to eliminate the effects of disease-causing mutations. We previously used adeno-associated virus (AAV) vectors to target and inactivate mutant COL1A1 genes in MSCs from individuals with the brittle bone disorder, osteogenesis imperfecta (OI). Here we have used AAV vectors to inactivate mutant COL1A2 genes in OI MSCs, thereby demonstrating that both type I collagen genes responsible for OI can be successfully targeted. We incorporated improved vector designs so as to minimize the consequences of random integration, facilitate the removal of potential antigens, and avoid unwanted exon skipping. MSCs targeted at mutant COL1A2 alleles produced normal type I procollagen and formed bone, thereby demonstrating their therapeutic potential.

Original languageEnglish (US)
Pages (from-to)187-193
Number of pages7
JournalMolecular Therapy
Volume16
Issue number1
DOIs
StatePublished - Jan 2008

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta'. Together they form a unique fingerprint.

  • Cite this

    Chamberlain, J. R., Deyle, D. R., Schwarze, U., Wang, P., Hirata, R. K., Li, Y., Byers, P. H., & Russell, D. W. (2008). Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta. Molecular Therapy, 16(1), 187-193. https://doi.org/10.1038/sj.mt.6300339